Ablynx: Publication in Accordance With Article 14 of the
Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")
GHENT, BELGIUM -- (Marketwire) -- 10/23/12 -- Ablynx (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Sofinnova Partners SAS and Gilde Europe Food & Agribusiness Fund BV.
Sofinnova Partners SAS has dropped below the 15% threshold and Gilde Europe Food & Agribusiness Fund BV has dropped below the 3% threshold.
Full versions of all transparency notifications are available on the website of Ablynx, section Investors.
About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(R), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
pdf version of the press release : http://hugin.info/137912/R/1651655/532892.pdf
For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: firstname.lastname@example.org
Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: email@example.com Follow us on Twitter @AblynxABLX
M:Communications: Mary-Jane Elliott Amber Bielecka Claire Dickinson t: +44 207 920 2330 e: firstname.lastname@example.org